ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1370

The Association of Body Mass Index (BMI) and Radiographic Progression of Joint Disease in Rheumatoid Arthritis (RA)

Christine K. Iannaccone1, Jing Cui2, K P Liao3, Jonathan S. Coblyn3, Michael Weinblatt4 and Nancy A. Shadick5, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Rheumatology, Brigham and Womens Hospital, Boston, MA, 3Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, 5Brigham and Women's Hospital/Harvard University, Cambridge, MA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: body mass, joint damage and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality

Session Type: Abstract Submissions (ACR)

Background/Purpose

Previous studies suggest that lower BMI is associated with progression of radiographic joint damage in RA but little is known about the biological role BMI plays in radiographic joint damage and research outcomes of the association have varied. Whether the association of BMI and radiographic joint damage may be mediated by disease activity variables is currently unknown. Using a cohort of RA patients, this study aims to examine the relationship between BMI and radiographic joint damage and disease activity.

Methods

We analyzed data from a longitudinal RA cohort study. The data collection included joint examinations, blood draws and patient reported outcome measures over 10 years. Hand and wrist radiographs were acquired at baseline and 2 years and scored by the van der Heijde-modified Sharp score method (vdHSs) (n=543). We created a dichotomous outcome variable for radiologic progression; defining patients with radiographic progression as having a change of ≥ 10 units in total vdHSs over two years. We conducted univariate analyses to assess predictors of radiographic joint damage progression that included age, gender, BMI group (underweight BMI <20kg/m2, normal BMI 20-24.9 kg/m2, overweight BMI 25-29.9 kg/m2, obese BMI ≥30kg/m2 (Baker et al, 2011)), DAS28-CRP4, anti-TNF use and anti-CCP status. For our primary analysis, we constructed a multivariate logistic regression model to study the effect between BMI and radiographic progression.

Results

We studied 543 patients with a mean age (SD) of 57.6 (12.7) years and a mean disease duration of 14.4 (12.2) years. Eighty-three percent were female and 68.3% were anti-CCP+; 69 (12.7%) of the patients had progression of joint damage. In the univariate analysis, BMI (group), anti-CCP+, and DAS28-CRP4 were all associated with radiographic joint damage, but age, gender and anti-TNF use did not show any association. The multivariate logistic regression analyses showed that patients who were underweight or normal weight had a significantly increased odds (OR=4.85, 95%CI 1.76-9.05; OR=3.99, 95%CI 1.76-9.05) of having radiographic progression compared to patients who were obese. Having a higher DAS28-CRP4 score was associated with greater odds of having radiographic joint damage (Table).

Conclusion

We found that lower BMI was associated with radiographic joint damage progression in RA, independent of disease activity. Further work is necessary to understand the biological role BMI plays in radiographic joint damage progression, as well as the involvement of inflammation in the relationship between BMI and progression of joint disease in RA. 

Association of BMI and radiologic progression of joint disease in RA

Multivariate Logistic Regression Model*

Odds Ratios

Confidence Intervals

BMI (underweight vs. Obese)

4.85

1.34-17.53**

BMI (Normal vs. Obese)

3.99

1.76-9.05

BMI (Overweight vs. Obese)

1.65

0.68-4.02

DAS28-CRP4 (continuous)

1.28

1.08-1.51

Anti-CCP Positive

1.85

0.96-3.57

*adjusted for age and gender

**test for trend of BMI group and radiologic progression p=0.0006


Disclosure:

C. K. Iannaccone,
None;

J. Cui,
None;

K. P. Liao,
None;

J. S. Coblyn,

CVS caremark,

5;

M. Weinblatt,

BMS, UCB, Crescendo Bioscience,

2,

Medimmune, AstraZeneca, Amgen, Abbvie, BMS, Crescendo Bioscience, Lilly, Pfizer, UCB, Roche,

5;

N. A. Shadick,

Crescendo Bioscience,

2,

Amgen,

2,

UCB,

2,

Abbvie,

2,

Bristol Myers Squibb,

2,

Genentech ,

2.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-of-body-mass-index-bmi-and-radiographic-progression-of-joint-disease-in-rheumatoid-arthritis-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology